These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1919635)

  • 21. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.
    Milpied N; Fielding AK; Pearce RM; Ernst P; Goldstone AH
    J Clin Oncol; 1996 Apr; 14(4):1291-6. PubMed ID: 8648386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
    van Besien K; Thall P; Korbling M; Pugh WC; Khouri I; Mehra R; Giralt S; Anderlini P; Amin K; Mirza N; Seong D; Gajewski J; Hester J; Andersson B; Cabanillas F; Champlin R; Przepiorka D
    Biol Blood Marrow Transplant; 1997 Aug; 3(3):150-6. PubMed ID: 9310192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.
    Peggs KS; Hunter A; Chopra R; Parker A; Mahendra P; Milligan D; Craddock C; Pettengell R; Dogan A; Thomson KJ; Morris EC; Hale G; Waldmann H; Goldstone AH; Linch DC; Mackinnon S
    Lancet; 2005 Jun 4-10; 365(9475):1934-41. PubMed ID: 15936420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The frequency of pretransplant donor cytotoxic T cell precursors with anti-host specificity predicts survival of patients transplanted with bone marrow from donors other than HLA-identical siblings.
    Roosnek E; Hogendijk S; Zawadynski S; Speiser D; Tiercy JM; Helg C; Chapuis B; Gratwohl A; Gmür J; Seger R
    Transplantation; 1993 Sep; 56(3):691-6. PubMed ID: 8212168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
    Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.
    Anderson JE; Litzow MR; Appelbaum FR; Schoch G; Fisher LD; Buckner CD; Petersen FB; Crawford SW; Press OW; Sanders JE
    J Clin Oncol; 1993 Dec; 11(12):2342-50. PubMed ID: 8246023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors.
    Bearman SI; Mori M; Beatty PG; Meyer WG; Buckner CD; Petersen FB; Sanders JE; Anasetti C; Martin P; Appelbaum FR
    Bone Marrow Transplant; 1994 Jan; 13(1):31-5. PubMed ID: 8019451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
    Morris E; Thomson K; Craddock C; Mahendra P; Milligan D; Cook G; Smith GM; Parker A; Schey S; Chopra R; Hatton C; Tighe J; Hunter A; Peggs K; Linch D; Goldstone A; Mackinnon S
    Blood; 2004 Dec; 104(13):3865-71. PubMed ID: 15304395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation.
    Peniket AJ; Ruiz de Elvira MC; Taghipour G; Cordonnier C; Gluckman E; de Witte T; Santini G; Blaise D; Greinix H; Ferrant A; Cornelissen J; Schmitz N; Goldstone AH;
    Bone Marrow Transplant; 2003 Apr; 31(8):667-78. PubMed ID: 12692607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
    Collins RH; Shpilberg O; Drobyski WR; Porter DL; Giralt S; Champlin R; Goodman SA; Wolff SN; Hu W; Verfaillie C; List A; Dalton W; Ognoskie N; Chetrit A; Antin JH; Nemunaitis J
    J Clin Oncol; 1997 Feb; 15(2):433-44. PubMed ID: 9053463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
    van Besien KW; Mehra RC; Giralt SA; Kantarjian HM; Pugh WC; Khouri IF; Moon Y; Williams P; Andersson BS; Przepiorka D; McCarthy PL; Gajewski JL; Deisseroth AB; Cabanillas FF; Champlin R
    Am J Med; 1996 Mar; 100(3):299-307. PubMed ID: 8629675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.